Disease Information for Pramlintide (Symlin) Administration/Toxicity

Associated Diseases & Rule outs
Associated Disease & Complications
Hypoglycemia, diabetic/treatment
Disease Mechanism & Classification
DRUG/Anti-diabetic medication (example)
DRUG/Dose before meals
DRUG/New release 2006
DRUG/Novel drug/Class
DRUG/Novel anti-diabetic Incretin mimic/Amylin effect
PROCESS/Medication/Drug (CONFIRM dose/before treatment)
Pramlintide (Symlin) administration, Brand name/Pramlintide-Metreleptin combination ), Brand name/Symlin (Pramlintide)
Drug Dosage
DRUG/Dose 30 mcg injection
DRUG/Dose 60 mcgm injection
DRUG/Dose TID Medication
DRUG/Dose with meals
DRUG/Injectable medication (parenteral)
DRUG/Injectable preparation only

SYMLIN is used with insulin and has been associated with an increased risk of insulin-induced severe hypoglycemia, particularly in patients with type 1 diabetes; When severe hypoglycemia associated with SYMLIN use occurs, it is seen within 3 hours following a SYMLIN injection; careful patient instruction, and insulin dose adjustments are critical elements for reducing this risk; SYMLIN is the first in a new class of injected antihyperglycemic medications for use in patients with type 2 or type 1 diabetes treated with insulin; Pramlintide, the active ingredient in SYMLIN, is a synthetic analog of human amylin, a naturally occurring neuroendocrine hormone synthesized from pancreatic beta cells that contributes to glucose control during the postprandial period; Amylin, similar to insulin, is absent or deficient in patients with diabetes; When used with insulin, SYMLIN can help patients achieve improved glycemic control with additional benefits that cannot be realized with insulin alone;Amylin works in conjunction with insulin to help control blood glucose levels; Amylin is a neuroendocrine hormone that is cosecreted by the beta cells of the pancreas in response to food intake; While insulin works to regulate glucose disappearance from the bloodstream, amylin works to help regulate glucose appearance in the bloodstream from the stomach and liver;Patients with diabetes are amylin deficient

Reduces postprandial glucose excursions

Reduces glucose fluctuations throughout the day

Enhances satiety, leading to potential weight loss

Lowers mealtime insulin requirements

Improves A1C beyond the effect of insulin alone

Amylin exerts its actions after meals, therefore, replacing these effects is important in obtaining better glucose control. In patients who have failed to achieve desired glucose control despite optimal insulin therapy, SYMLIN therapy should also be considered.


External Links Related to Pramlintide (Symlin) Administration/Toxicity
PubMed (National Library of Medicine)
NGC (National Guideline Clearinghouse)
Medscape (eMedicine)
Harrison's Online (accessmedicine)
NEJM (The New England Journal of Medicine)